GUWS Medical

S

Sandostatin

GH secretagogue-induced GH release, 92 Sarcopenia

GHS, 326 Septo-optic dysplasia. 205 Serum insulin blood glucose glucose disappearance rate, 254f Serum prolactin. 209, 210 Serum triglycerides

Syndrome X and GHD, 251 Sex steroids

GH secretion, 202, 203 Sexual dimorphism

GH secretion, 203 Short stature, 180 children ethical issues, 212

GHS, 322 GH secretion, 201 Signal transduction GH receptor, 7, 8 Single-strand conformational polymorphism (SSCP) analysis GHAD, 183 Skeletal maintenance

GH, 234 Skeletal muscle mass reduction

GHD, 223 Sleep abnormalities

GH secretion, 273 GH, 9, 10 GHRH, 309 GHRP, 274, 275 GH secretion. 192, 261-276

development and aging, 269, 270 pathological states, 271, 272 plasma GH, 263f quality

GH administration, 273 GHRH, 274 somatostatin effects, 274 somatotropic axis, 272-276 Sieep stages nocturnal GH secretion, 264-269 Sleep-wake cycle

GH secretion, 261-264 manipulations, 262, 263 Slow-wave sieep aging, 271f GH profiles, 267f GH secretion, 264-268 pharmacological stimulation, 268, 269

Somatomedin-C. See IGF-1 Somatostatin, 1,171 effects sleep, 274 GH release, 120

GRF dose-response curves, ¡27, 128 neurons

GHRH neurons, 92, 93 receptor subtypes

G H secretion regulation, 109-135

secretion pulsatile secretion and regulatory mechanism, 192

tone obesity, 199 Somatotroph, GHD and, 205 Somatotropic axis sleep, 272-276 Somatotropin release-inhibiting factor (SR1F), 192, 203 GH secretion, 120 receptor cloning, ! 10, 111 desensitization, 113, 114 receptor subtypes, 110, 113

cellular mechanisms of action, J12 functions, 111, 112 Southern blot analysis

GHAD, i 83 Spiroindanylpi peri dine lead from screening benzolactam secretagogues, 50, 51 lead-modification amino acid side chain, 53t modifications, 54t optimization, 55t Spiropiperidine replacements, 611 Spontaneous GH secretory profiles, 207-211

Spontaneous pulsatile growth hormone secretion acute lymphoblastic leukemia (ALL), 198f SRIF-28, 110

SST-hypothalamic neurons GHRH, 3-7 GHS-R, 3-7 SSTR2, 111, 112

desensitization, 113, 114 ligand binding determinants. 114 structure-function analysis, 114 SSTR3, 111 SSTR5, 112 STATs, 179 Strength GHD, 225

Stress

GH secretion, 193, 194 Structure-activity relationships benzolactam secretagogucs, 48, 49 Suprachiastnatic nucleus (SCN)

GHS-R expression, 7 Syndrome X, 9 ' adult GHD, 250- 252 GH, 247—255 HPA axis, 249

0 0